Duality Biotherapeutics (FRA:4ZB) Change In Inventory: €0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4ZB Duality Biotherapeutics Inc FRA:4ZB
19 GF Score
Price €19.70
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics Change In Inventory?

Duality Biotherapeutics FRA:4ZB +6.49% 19 Change In Inventory is €0.0 Mil as of Jun. 2026. GuruFocus rates FRA:4ZB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Duality Biotherapeutics's change in inventory for the quarter that ended in Jun. 2026 was €0.0 Mil. It means Duality Biotherapeutics's inventory stayed the same from Dec. 2025 to Jun. 2026 .

Duality Biotherapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was €0.0 Mil. It means Duality Biotherapeutics's inventory stayed the same from Dec. 2024 to Dec. 2025 .

Duality Biotherapeutics's Total Inventories for the quarter that ended in Jun. 2026 was €0.0 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Duality Biotherapeutics's Days Inventory for the quarter that ended in Jun. 2026 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Duality Biotherapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.00.

Duality Biotherapeutics  (FRA:4ZB) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Duality Biotherapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0/57.441471999013*365 / 2
=0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Duality Biotherapeutics's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=57.441471999013 / 0
=N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Duality Biotherapeutics's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0 / 27.39471584378
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics Change In Inventory Related Terms

Duality Biotherapeutics Change In Inventory Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics Change In Inventory Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Change In Inventory
0.00 0.00 0.00 0.00

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
Change In Inventory 0.00 0.00 0.00
FRA:4ZB
19GF Score
Duality Biotherapeutics Inc FRA:4ZB
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of €0.0 Mil mean?
Duality Biotherapeutics (FRA:4ZB) has a Change In Inventory of €0.0 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Duality Biotherapeutics and its competitors.
Is Duality Biotherapeutics' Change In Inventory too high?
Duality Biotherapeutics' current Change In Inventory is €0.0 Mil. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Change In Inventory compare to VRTX and REGN?
Duality Biotherapeutics' Change In Inventory of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current Change In Inventory is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current Change In Inventory of €0.0 Mil. The current Change In Inventory is €0.0 Mil. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current Change In Inventory is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Duality Biotherapeutics Business Description

Other Exchanges 09606:Hong Kong
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score

Get the complete analysis for FRA:4ZB

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.70
Price